Cover Image
市場調查報告書

多囊性卵巢症候群:開發中產品分析

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232830
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
多囊性卵巢症候群:開發中產品分析 Polycystic Ovarian Syndrome - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 55 Pages
簡介

多囊性卵巢症候群(PCOS)是育齡期女性會發生的荷爾蒙(內分泌)障礙。其症狀有月經異常,痤瘡,毛髮稀疏,體重增加,雄激素過剩等。危險因素有家族病史,第二型糖尿病,心臟病等,可用荷爾蒙療法加以治療。

本報告提供多囊性卵巢症候群治療藥的開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

多囊性卵巢症候群概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Addex Therapeutics Ltd
  • Crinetics Pharmaceuticals, Inc.
  • EffRx Pharmaceuticals S.A.
  • Euroscreen S.A.
  • Merck KGaA
  • Millendo Therapeutics, Inc.
  • Vicore Pharma AB

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8411IDB

Summary

Global Markets Direct's, 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016', provides an overview of the Polycystic Ovarian Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
  • The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polycystic Ovarian Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Polycystic Ovarian Syndrome - Overview
    • Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis
  • Polycystic Ovarian Syndrome - Therapeutics under Development by Companies
  • Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Polycystic Ovarian Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Polycystic Ovarian Syndrome - Products under Development by Companies
  • Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes
  • Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Crinetics Pharmaceuticals, Inc.
    • EffRx Pharmaceuticals S.A.
    • Euroscreen S.A.
    • Merck KGaA
    • Millendo Therapeutics, Inc.
    • Vicore Pharma AB
  • Polycystic Ovarian Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • C-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • choriogonadotropin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDSCR-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metformin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MLE-4901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polycystic Ovarian Syndrome - Dormant Projects
  • Polycystic Ovarian Syndrome - Discontinued Products
  • Polycystic Ovarian Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
      • Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
      • Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
      • Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
      • Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
      • Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
      • Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
      • Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
      • Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
      • Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016
  • Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics, Inc., H2 2016
  • Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Polycystic Ovarian Syndrome - Dormant Projects, H2 2016
  • Polycystic Ovarian Syndrome - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016
  • Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top